Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

228 10 The Immune System in Cancer: If It Isn't Broken, Can We Fix It?
62 Basu S, Binder RJ, Suto R, Anderson
KM, Srivastava PK. Necrotic but
not apoptotic cell death releases heat
shock proteins, which deliver a partial
maturation signal to dendritic cells and
activate the NF-kB pathway. Int Immunol
2000; 12: 1539±1546.
63 Gallucci S, Lolkema M, Matzinger P.
Natural adjuvants: endogenous activators
of dendritic cells. Nat Med 1999; 5:
1249±1255.
64 Fuchs EJ, Matzinger P. Is cancer dangerous
to the immune system? Semin
Immunol 1996; 8: 271±280.
65 Todryk S, Melcher AA, Hardwick N,
Linardakis E, Bateman A, Colombo
MP, Stoppacciaro A,Vile RG. Heat
shock protein 70 induced during tumor
cell killing induces Th1 cytokines and
targets immature dendritic cell precursors
to enhance antigen uptake. JImmunol
1999; 163: 1398±1408.
66 Savill J, Fadok V. Corpse clearance defines
the meaning of cell death. Nature
2000; 407: 784±788.
67 Ishii KJ, Suzuki K, Coban C,Takeshita
F, Itoh Y, Matoba H, Kohn LD,
Klinman DM. Genomic DNA released
by dying cells induces the maturation of
APCs. J Immunol 2001; 167: 2602±2607.
68 Vabulas RM, Pircher H, Lipford GB,
Hacker H,Wagner H. CpG-DNA activates
in vivo T cell epitope presenting
dendritic cells to trigger protective antiviral
cytotoxic T cell responses. J Immunol
2000; 164: 2372±2378.
69 Piacentini M. Apoptosis and autoimmunity:
two sides to the coin. Cell Death
Differ 1999; 6: 1±2.
70 Ren Y, Savill J. Apoptosis: the importance
of being eaten. Cell Growth Differ
1998; 5: 563±568.
71 Matzinger P. Tolerance, danger and
the extended family. Annu Rev Immunol
1994; 12: 991±1045.
72 Kalled SL, Cutler AH, Burkly LC.
Apoptosis and altered dendritic cell
homeostasis in lupus nephritis are limited
by anti-CD154 treatment. J Immunol
2001; 167: 1740±1747.
73 Seery JP, Cattell V,Watt FM. Cutting
edge: amelioration of kidney disease in
a transgenic mouse model of lupus nephritis
by administration of the caspase
inhibitor carbobenzoxy-valyl-alanyl-aspartyl-(b-O-methyl)-fluoromethylketone.
J Immunol 2001; 167: 2452±2455.
74 Kurts C, Miller JFAP, Subramaniam
RM, Carbone FR, Heath WR.
Major histocompatibility complex class
I-restricted cross-presentation is biased
towards high dose antigens and those
released during cellular destruction.
J Exp Med 1998; 188: 409±414.
75 Ronchetti A, Rovere P, Iezzi G, Galati
G, Heltai S, Pia Protti M, Paola
Garancini M, Manfredi AA, Rugarli
C, Bellone M. Immunogenicity of
apoptotic cells in vivo: role of antigen
load, antigen-presenting cells, and cytokines.
J Immunol 1999; 163: 130±136.
76 Ludewig B, Ochsenbein AF, Odermatt
B, Paulin D, Hengartner H,
Zinkernagel RM. Immunotherapy
with dendritic cells directed against tumor
antigens shared with normal host
cells results in severe autoimmune disease.
J Exp Med 2000; 191: 795±804.
77 Kugler A, Stuhler G,Walden P, Zoller
G, Zobywalski A, Brossart P,
Trefzer U, Ullrich S, Muller CA,
Becker V, Gross AJ, Hemmerlein B,
Kanz L, Muller GA, Ringert RH. Regression
of human metastatic renal cell
carcinoma after vaccination with tumor
cell±dendritic cell hybrids. Nat Med
2000; 6: 332±336.
78 Huang AYC, Golumbek P, Ahmadzadeh
M, Jaffee E, Pardoll D, Levitsky
H. Role of bone marrow derived
cells in presenting MHC class I-restricted
tumor antigens. Science 1994;
264: 961±965.
79 Huang AYC, Bruce AT, Pardoll DM,
Levitsky HI. In vivo cross-priming of
MHC class I-restricted antigens requires
a TAP transporter. Immunity
1996; 4: 349±355.
80 Levitsky HI, Lazenby A, Hayashi RJ,
Pardoll D. In vivo priming of two distinct
antitumor effector populations:
the role of MHC class I expression.
J Exp Med 1994; 179: 1215±1224.
81 Cayeux S, Richter G, Becker C, Pezzutto
A, Dorken B, Blankenstein T.
Direct and indirect T cell priming by
dendritic cell vaccines. Eur J Immunol
1999; 29: 255±234.